Exclusive Market Insight & Professional Analysis: The most comprehensive resource center for the biotech industry

        Sign Up Today! Get started for all the insight you want!
  • Exclusive Posts

  • Industry Newsletters

  • Clinical Trials

  • Therapeutic Vaccines

  • Development-Stage Firm

  • Genomics

  • Gene Analysis

  • RNA Analysis

  • Possible Approvals

  • Stock Table

  • Possible Takeovers

  • Technology of the Week

  • Prohost Picks

  • And much more...


ImmunoGen: What About Now?

  Friday, April 28, 2017

ImmunoGen is one of two firms Prohost selected for investment on February 2011 based on the promises of its novel antibody-drug conjugate (ADC). An ADC drug is an antibody that carries highly potent cancer-killing agent attached to the antibody by a linker. The linker is designed to release an exceptionally toxic agent only as the ADC reaches the cancer cells in order not to harm or kill healthy cells. Our enthusiasm for ADC products emanates from their potency compared to other antibodies and to their safety and potency compared to chemotherapy drugs. The dosage of the toxic agent in the monoclonal antibody conjugate is several times that of chemotherapy, hence the superior potency and tolerability expected from the ADC products.        More...

The Market Reaction Towards the FDA Complete Response Letter Offers a Unique Investment Opportunity In Incyte

  Monday, April 17, 2017

Eli Lilly (LLY) and Incyte (INCY) announced that the FDA has issued a complete response letter for the New Drug Application (NDA) of baricitinib for moderate-to-severe rheumatoid arthritis (RA). More...

Neurocrine Biosciences: The Meaning of Ingrezza's Approval for Tardive Dyskinesia (TD)

  Thursday, April 13, 2017

On March 27, we wrote about how positive results of Neurocrine Biosciences (NBIX) drug Ingrezza on Tardive Dyskinesia (TD) will highlight Neurocrine Biosciences and its Scientists. We wrote: The results published online by The American Journal of Psychiatry demonstrate that Phase 3 trial with Ingrezza conducted on patients with tardive dyskinesia showed significant and meaningful reduction in symptoms. We elaborated on the trial that provided the results on 234 subjects with tardive dyskinesia (TD) and mood disorder (including bipolar disorder or major depressive disorder) and how the patients were treated with Neurocrine drug.    More...

The FDA Approves Gilead's HCV Drugs Harvoni and Sovaldi for Adolescents

  Sunday, April 09, 2017

The FDA Approves Harvoni® and Sovaldi® in Pediatric  More...

Neurocrine BioSciences (NBIX): Time for Transformation and Achievements

  Monday, March 27, 2017

Positive Results of INGREZZA on Tarditive Dyskinesia Highlights Neurocrine Biosciences Sciences and Scientists     More...

OncoCyte's Liquid Biopsy Test Has Positive News

  Wednesday, March 15, 2017

OncoCyte (OCX) has news. This firm, which develops non-invasive blood and urine liquid biopsy diagnostic tests has good news about its lung cancer liquid biopsy. Liquid biopsy is a term recently coined for a simple blood test that can replace current invasive and expensive biopsy procedures for the detection of cancers at their early stages. This simple blood test is expected to lessen the need for invasive diagnostic methods such as surgical biopsies and cystoscopic procedures.    More...

Lexicon Pharmaceuticals: Cultivating the Fruits From Years of Lucrative Research

  Monday, March 06, 2017

A few days ago, the FDA approved Lexicon Pharmaceutical’s (LXRX) drug Xermelo™ (telotristat ethyl) 250 mg for the treatment of metastatic neuro-endocrine syndrome (mNET) patients who suffer from carcinoid syndrome diarrhea. The drug will be launched and sold today, March 6, in select specialty pharmacies.  More...

Exelixis: Important Collaborative Agreements with Roche and Bristol-Myers Squibb

  Monday, February 27, 2017

Exelixis (EXEL) announced a new collaboration with Roche on a phase 1b dose escalation study of a combination of Exelixis cabozantinib in combination with Roche’s anti-PD-L1 immuno-therapy drug atezolizumab. The study aims at evaluating the safety and tolerability  of the combination in patients with locally advanced or metastatic solid tumors. Enrollment is scheduled to begin mid-year 2017; Exelixis will sponsor the trial, and Roche will provide atezolizumab.  More...

Agenus: Why Canceling Prophage Trial Should Not be Concerning

  Wednesday, February 22, 2017

Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore with Agenus’ totally changed status now with its new immunotherapy pipeline. The new checkpoint inhibitors products and their checkpoint targets products are the talk of the cancer community and having them has attracted large companies, including Incyte.  More...

Seattle Genetics' Agreement with Immunomedics: The Benefit Vs. the Risk

  Tuesday, February 14, 2017

Immunomedics (IMMU) and Seattle Genetics (SGEN) announced an exclusive global licensing agreement enabling Seattle Genetics to develop, fund, manufacture, and commercialize Immunomedics' solid tumor drug candidate IMMU-132.  More...

Join our FREE Email Updates, with the latest insight information about the biotech industry